A simple and isocratic HPLC method with stability indicating nature was developed and then subsequently validated for simultaneous determination of ciprofloxacin and dexamethasone in pharmaceutical formulations, human serum and urine. Best chromatographic separations were attained within run time of 10 minutes using C8 as stationary phase and mixture of phosphate buffer and methanol (41:59 v/v) as mobile phase. The mobile phase was flowed at 1.5 mL min -1 with detection of both the analytes at 270 nm using photodiode array detector. Validation of the method was accomplished using specificity, linearity, accuracy, precision, robustness, LOD and LOQ. The method was found linear from 3-21 mg mL -1 for ciprofloxacin (r 2 ≥ 0.999) and 1-7 mg mL -1 for dexamethasone (r 2 ≥ 0.999). The %age recoveries of ciprofloxacin in spiked human urine and serum were ≥99% and ≥85% respectively, while for dexamethasone they were ≥97% in both matrices. The method proficiently separated the peaks of ciprofloxacin and dexamethasone from all types of interfering substances including degradation products/impurities with purity index ≥ 0.9998. The method thus was stability-indicating and can be employed for simultaneous analysis of ciprofloxacin and dexamethasone in complex matrices involving multiple components in the mixture. 
1-INTRODUCTION

Ciprofloxacin
(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid), a well-known antibiotic, is used to relieve bacterial infections of the eyes, corneal ulcers along with some common bacterial attacks. Dexamethasone (8S,9R,10S,11S,13S,14S,1 6R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-, 7,8,9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a] phenanthren-3-one [ Figure 1 ] a corticosteroid, is used to relieve bacterial ocular infections that require corticosteroid [1] . Many authors have reported a lot of different analytical methods for both drugs individually utilizing different techniques like HPLC [2] [3] [4] [5] [6] [7] [8] [9] , spectrophotometry and spectrofluorometric [10] [11] [12] [13] , titrimetric [14] methods for ciprofloxacin while for dexamethasone different methods involving HPLC, GC and TLC are reported [15] [16] [17] [18] [19] [20] [21] .
also the enforcement agencies in general to monitor the quality of the marketed products.
2-EXPERIMENTAL
Chemicals and Reagents
Ciprofloxacin (99.87%) and dexamethasone (99.96%) reference standards were received from Schazoo Zaka Laboratories (Lahore, Pakistan) and were used as such without further refinement. Commercial products (Zoxan D and Ciprodex) containing 3 mg mL -1 ciprofloxacin and 1 mg mL -1 dexamethasone were analyzed during the current research work. All the chemicals used were of either HPLC grade or highest grade available commercially and were used as such. Double distilled water, other liquids used in mobile phase and all the injecting solutions were subject to filtration employing 0.45 mm nylon filters (Millipore, USA).
Equipment and Chromatographic Conditions
All the chromatographic work was conducted on LC-20A system (Shimadzu, Japan) using PDA detector at 270 nm. Each time 20 mL volume of analytes were injected using the fixed loop and peak areas of ciprofloxacin and dexamethasone were integrated using system built software. For separation, Hypersil BDS C8 column (250 X 4.6 mm, 5 mm) was used at room temperature. Pre-mixed mobile phase was used which was prepared by mixing 59:41 v/v ratio of methanol and 0.018M phosphate buffer (pH 3.0) and was flowed at 1.5 mL min -1 . pH 3.0 phosphate buffer was made by dissolving 2.448 g of potassium dihydrogen phosphate in 1L water, followed by 1 mL triethylamine (TEA) and finally adjustment of the pH to 3.0 with dilute phosphoric acid.
Preparation of Stock Solution (A)
To prepare the stock solution (A) of 300 mg mL -1 ciprofloxacin and 100 mg mL -1 dexamethasone respectively, 30 mg ciprofloxacin and 10 mg dexamethasone were accurately weighed and then transferred to 100 mL volumetric flask. The analytes were sonicated for about 8-10 minutes in small amount of methanol and finally marked to the volume using mobile phase.
Preparation of Working Standard Solution (B)
The working standard solution was prepared by diluting stock solution (A) to 25 times with mobile phase to get working standard solution (B) of 12 mg mL -1 ciprofloxacin and 4 mg mL -1 dexamethasone.
Preparation of Sample Solution
To prepare the sample solution, commercial eye drop was diluted 250 times with mobile phase to get 12 mg mL -1 ciprofloxacin and 4 mg mL
dexamethasone.
Preparation of Human Urine Samples
Human urine (50 mL) was spiked with 50 mL stock solution (A), gently mixed for 2 minutes and then centrifuged for 10 minutes at 4000 rpm. 80 Although fixed dose combination (FDC) of both the investigating drugs is available commercially as eye drops, however this FDC has not been listed in any of the common pharmacopoeia. Reviewing the literature resulted in the occurrence of few methods for this FDC [22] [23] , however no stability indicating HPLC method was found for this FDC. We are involved recently to conduct research relating to method development of FDC of different drugs with varying chemical properties and many of these papers have been reported in the literature [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . In order to fill this knowledge gap, it was attempted to develop and validate HPLC method with stability indicating properties for this FDC (ciprofloxacin and dexamethasone) not only in commercial formulations but also in human serum and urine. We hope, the inclusion of this knowledge in the existing literature will help the pharmaceutical industries in large to maintain the quality of their products containing these active ingredients and mL of this solution was diluted with 920 mL of the mobile phase and mixed for 2 minutes to get the final concentration of 12 mg mL -1 and 4 mg mL -1 for ciprofloxacin and dexamethasone respectively.
Preparation of Human Serum Samples
Proteins were precipitated before the direct injection of human serum into the HPLC system. To precipitate proteins and inject analytes directly, human serum (200 mL) was spiked with stock solution (40 mL), followed by addition of 760 mL mobile phase. The resulting solution was subjected to centrifugation for 10 minutes at 4000 rpm to get protein-free analytes. This results in achieving concentration of 12 mg mL -1 ciprofloxacin and 4 mg mL -1 dexamethasone.
Linearity
To get the linear calibration curves and to calculate the correlation coefficient, seven mixed standard solutions in the ranges of 3-21 mg mL -1 (3, 6, 9, 12, 15, 18 and 21µg mL -1 ) for ciprofloxacin and 1-7 mg mL -1 (1, 2, 3, 4, 5, 6 and 7 µg mL -1 ) for dexamethasone were prepared. Triplicate injections of each mixed standard solution were conducted.
Accuracy
To carryon accuracy, standard analytes in mixed mode were spiked in common excipients present in ophthalmic preparations, human urine and serum. Three different levels of solutions ranging from 50-150 % of the nominal concentrations were spiked to the mixture of benzalkonium chloride and NaCl (in aqueous base), human urine and serum.
Precision
Precision was evaluated in terms of intra-day and inter-day precision. To evaluate, intra-day precision, three different concentrations of standard analytes were injected within same day, whereas for intra-day precision, same solutions (placed in dark) were analyzed singly for three consecutive days. Relative standard deviation of the peak area was then conducted to check the level of precision.
Specificity (Stress Testing)
ICH recommended stress conditions like acidic, basic, oxidative, thermal and photolytic stresses were applied to demonstrate specificity of the method.
Acid Degradation Studies
To perform acid stress studies, a mixture of stock solution (1 mL) and 5 M HCl (1 mL) in 25 mL volumetric flask was kept for 22 hour at 40 0 C/75% RH, followed by neutralizing the excess acid using 5 M NaOH. This was then further marked up to 25 mL with mobile phase.
Base Degradation Studies
To perform basic stress studies, two separate 25 mL volumetric flask each containing a mixture of stock solution (1 mL) and 5 M NaOH (1 mL) were kept in environmental test chamber at different environmental conditions. One flask was placed for 16 hours and other for 45 minutes at 40 0 C/75% RH, followed by neutralizing the excess base using 5 M HCl. This was then further marked up to 25 mL with mobile phase.
Oxidative Degradation Studies
To perform oxidative stress studies, a mixture of stock solution (1 mL) and 6 % H 2 O 2 (1 mL) in 25 mL volumetric flask was kept for 22 hour at 40 0 C/75% RH, followed by marking the volume up to 25 mL with mobile phase.
Thermal Degradation Studies
To perform thermal stress studies, stock solution (1 mL) taken in 25 mL volumetric flask was kept for 22 hour at 40 0 C/75% RH, followed by marking the volume up to 25 mL with mobile phase.
Photolytic Degradation Studies
To perform photolytic stress studies, stock solution (1 mL) taken in 25 mL volumetric flask was kept for 1.25 hours in direct sunlight, followed by marking the volume up to 25 mL with mobile phase.
Robustness
For the determination of method robustness prearranged deviation in the investigational circumstances was done. For this purpose, slight deviations were deliberately performed in the HPLC operating conditions like composition, rate of flow and buffer solution pH. The effect of these deviations was checked on the separation parameters.
Limit of detection and limit of quantitation
Signal-to-noise (S/N) ratio approach was adopted to calculate LOD and LOQ. For LOD and LOQ values, solutions of decreasing concentration were prepared by spiking known amounts of analytes into different matrices. The spiked solutions were injected in descending order to determine the S/N ratio. For LOQ S/N ratio of 10:1 while for LOD S/N ratio of 3:1 was used.
3-RESULTS AND DISCUSSION
Development of stability indicating RP-HPLC methods for analysis of drugs in pharmaceutical formulations, human serum and urine received much attention because of their importance in routine quality control, stability analysis and pharmacokinetic studies. In liquid chromatographic analysis, the selection of appropriate chromatographic conditions (stationary phase and mobile phase) is very important because lots of stationary phases and mobile phases can be selected. The chemistry of separating analytes plays a role when selecting appropriate chromatographic conditions. Ciprofloxacin and dexamethasone drugs can be separated through reverse-phase stationary phases because of containing major non-polar groups as well as containing unsaturated π electrons as demonstrated in our previous studies [28, 36] . Polar stationary phases like cyano, can also be used as groups like (-COOH, -OH or F etc.) are also found in these two analytes.
In this study a simple and precise RP-HPLC method with stability indicating nature was developed to analyze ciprofloxacin and dexamethasone simultaneously. With the purpose to get well resolved/symmetrical and impurity free peaks, changes were made in the mobile phase composition and pH of mobile phase as well as selection of different polar and non-polar columns with different lengths were used for ciprofloxacin and dexamethasone combination.
Optimization of Mobile Phase and Stationary Phase
During initial experiments, dexamethasone peaks showed high tailing on C18, Phenyl-2, and Cyano columns but symmetrical/good peak on C8 [28, 36] . However when same conditions were applied to ciprofloxacin using C8 column, tailed peak (tailing factor 1.99) was observed. Later adjustments in the composition of the buffer and methanol as well as pH of the buffer solution resulted in the separation of both the analytes as well as complete separation from the degradation products. The separation of analytes under different pH conditions have been shown in Figure 2 . On the basis of these results, the final composition of the mobile phase used was, methanol: phosphate buffer 0.018M, pH 3.0 (59:41,v/v) containing 0.1 % TEA that resulted in good/symmetrical peaks at retention times of 3.522, and 7.628 min, respectively. , injection volume 20 µL, wavelength 270nm.
Analytical Method Validation
ICH guidelines were brought into force when validating the analytical method [37] . The description and results of the validation parameters have been summarized below.
To get the linear calibration curves and to calculate the correlation coefficient, seven mixed standard solutions in the ranges of 3-21 mg mL -1 (3, 6, 9, 12, 15, 18 and 21µg mL -1 ) for ciprofloxacin and 1-7 mg mL -1 (1, 2, 3, 4, 5, 6 and 7 µg mL -1 ) for dexamethasone were prepared. Triplicate injections of each mixed standard solution were conducted. Linear regression equation for ciprofloxacin was found to be Y= 268966 X + 16692 with correlation coefficient ≥0.999 whereas for dexamethasone, it was Y= 17341 X + 439.57 with correlation coefficient ≥ 0.999.
For LOD and LOQ values, solutions of decreasing concentration were prepared by spiking known amounts of analytes into different matrices. The LOD was 0.169 µg mL -1 and 0.07 µg mL -1 for ciprofloxacin and dexamethasone, respectively whereas LOQ was 0.573 µg mL -1 and 0.187 µg mL -1 for ciprofloxacin and dexamethasone, respectively. To carryon accuracy, standard analytes in mixed mode were spiked in common excipients present in ophthalmic preparations, human urine and serum. Three different levels of solutions ranging from 50-150 % of the nominal concentrations were spiked to the mixture of benzalkonium chloride and NaCl (in aqueous base), human urine and serum. Recoveries of the analytes calculated during the current study are given in Table 1 which witnessed high recoveries. Precision was evaluated in terms of intra-day and inter-day precision. To evaluate, intra-day precision, three different concentrations of standard analytes were injected within same day, whereas for intra-day precision, same solutions (placed in dark) were analyzed singly for three consecutive days. Relative standard deviation of the peak area was then conducted to check the level of precision. Results shown in Table 2 agree with high precision.
For the determination of method robustness prearranged deviation in the investigational circumstances was done. For this purpose, slight deviations were deliberately performed in the HPLC operating conditions and results in separation parameters (3a and 3b) were calculated. Observed results revealed the method to be highly robust. To evaluate specificity, ICH prescribed different stress conditions like acid, base, thermal, oxidative and photolytic were applied to both the analytes in mixed form. Chromatograms under different stress environments are shown in Figure 3 whereas the results are summarized in Table 4 . The different stresses applied were strong enough the cause degradation for both the analytes. When comparing the stability of both the drugs, it was revealed that dexamethasone was more vulnerable to degradation than ciprofloxacin. When both the drugs were brought in acidic environment, both the drugs showed almost parallel degradation (about 91 %). Similar degradation results were obtained under basic, thermal and oxidative environment with almost same amount of degradation for both the analytes as was observed under acidic environment. In case of photolytic stress, the dexamethasone showed the same amount of degradation as was achieved in previous stresses environments, however the amount of degradation for ciprofloxacin was only 15 %. From all the stress environments in which both drugs were submitted, it was concluded that both the drugs were not stable under the stresses involved. In addition, there was similarity in the degradation profile of both the drugs under photolytic and basic environments.
Further to the amount of degradation, when evaluated for the degradation products generated, it was found that the number of degradation products/ impurities generated in different stress environments were different. For example, the number of impurities produced under acid, photolytic and basic stresses were 6, followed by two impurities peaks under thermal and oxidative stress. In case of all the stress conditions applied, all the impurities peaks were fully resolved from analyte peaks that prove the method to be stability indicating. The developed method was finally applied to determine both the analytes in their fixed dose combination as well as in spiked human urine and serum. The results presented in Table 5 and shown in figure 4 showed good recoveries and shows its suitability for intended purpose.
4-CONCLUSION
A simple and isocratic HPLC method with stability indicating nature was developed and then subsequently validated for simultaneous determination of ciprofloxacin and dexamethasone in pharmaceutical formulations, human serum and urine. Validation of the method was accomplished using specificity, linearity, accuracy, precision, robustness, LOD and LOQ. The method was proved simple, do not involve any ion pairing agent and also neither involve the much time taken liquid-liquid extraction not the more expensive solid phase extraction. The method was more efficient to separate both the analytes not only from each other but also from induced degradation products which make its suitability for routine as well as stability and bio-equivalence studies. 
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